|
|
|
|
||
Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details.Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details CALGARY, June 15, 2016 /CNW/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has dosed the first patient in its Phase 1 clinical trial for ZEN-3694 in metastatic Castration Resistant Prostate Cancer ("mCRPC") patients. In the Phase 1 trial, Zenith will be evaluating the safety, pharmacokinetics, and efficacy of ZEN-3694 as a single agent and in combination with the current standard of care enzalutamide. Zenith has also implemented a rich translational program to measure target modulation and to identify potential biomarkers for selecting patient subsets most likely to benefit from BET inhibition. Surprised that we're not further along. I was hoping that we were already one month or more into dosing! Not many options available to these men, so why did it take so long to get these locations up and recruiting? McCaffrey needs to inform us of the new timeline re early news on this trial, as I'll be surprised if he sticks to his earlier talk of news by summer. Study Start Date: April 2016 Locations United States, California University of California Los Angeles Medical Center Not yet recruiting Los Angeles, California, United States University of California San Francisco Medical Center Recruiting San Francisco, California, United States United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States Karmanos Cancer Institute Recruiting Farmington Hills, Michigan, United States United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States United States, Virginia Virginia Oncology Associates Recruiting Hampton, Virginia, United States Virginia Oncology Associates Recruiting Norfolk, Virginia, United States Sponsors and Collaborators Zenith Epigenetics Corp. https://clinicaltrials.gov/ct2/show/NCT02705469?term=zenith+epigenetics&rank=2 F6 |
return to message board, top of board |